UofL Health – UofL Hospital physicians and laboratory scientists faced challenges in the ordering of autoimmune and paraneoplastic panels: duplicate orders that add unnecessary cost and omitted test orders that could provide the key to the right diagnosis for patients.

Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in situ hybridization (FISH) panels, rather than chromosome studies.